Table 2. The effect of fresh cycle stimulation characteristics on thaw cycle outcomes
  Survival rate
Mean ± SD
Total cases
n=104
p-value Progression rate
N (%)
Total Survived
n=94
p-value Pregnancy rate
N (%)
Transferred
n=84
p-value
Protocol type:   0.87**   0.94****   0.58****
Antagonist 84.9±33.4   17/23 (73.9%)   4/21 (19.1%)  
Long agonist 82.6±36   45/66 (68.2%)   19/59 (32.2%)  
Short agonist 90±22.4   4/5 (80%)   1/4 (25%)  
Stimulation drug:   0.05*   0.01***   0.57***
FSH 76.9±38   28/46 (60.9%)   10/39 (25.6%)  
FSH/LH 90.1±29.7   38/48 (79.2%)   14/45 (31.1%)  
Endometrial thickness   0.96*   0.62***   0.84***
≤1cm 83.4±33.8   32/44 (72.7%)   11/40 (27.5%)  
> 1cm 83.7±35.8   34/50 (68%)   13/44 (29.6%)  
Endometrial grading:   0.61**   0.98***   0.35****
A 86.6±30.6   7/10 (70%)   4/10 (40%)  
B 87.6±30.5   22/32 (68.8%)   9/26 (34.6%)  
C 80.6±37.8   37/52 (71.2%)   11/48 (22.9%)  
Indication of freezing:   0.73**   0.84****   0.05***
Excess 82.4±35.7   48/68 (70.6%)   22/62 (35.4%)  
OHSS 85.8±33.3   16/24 (66.7%)   2/20 (10%)  
Thin endometrium 100±0   2/2 (100%)   0/2 (0%)  
Outcome of 1stcycle:   0.78**   0.68***   <0.0001****
No pregnancy 85.7±31.8   24/36 (66.7%)   4/33 (12.1%)  
Pregnancy 80.5±38.3   27/35 (77.1%)   18/32 (56.3%)  
No ET 85.2±33.8   15/23 (65.2%)   2/19 (10.5%)  
*Unpaired T test **one way ANOVA ***Chi square test ****Fisher-Freeman-Halton exact